ADMA Biologics (NASDAQ:ADMA) vs. Vericel (NASDAQ:VCEL) Head to Head Review

Vericel (NASDAQ:VCEL) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Vericel and ADMA Biologics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0	0	7	0	3.00
ADMA Biologics	0	0	3	1	3.25

Vericel presently has a consensus target price of $57.71, suggesting a potential upside of 4.05%. ADMA Biologics has a consensus target price of $21.25, suggesting a potential downside of 1.02%. Given Vericel’s higher probable upside, equities analysts plainly believe Vericel is more favorable than ADMA Biologics.

Profitability

This table compares Vericel and ADMA Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vericel	1.56%	1.48%	0.96%
ADMA Biologics	17.80%	53.20%	26.07%

Earnings & Valuation

This table compares Vericel and ADMA Biologics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$197.52 million	13.86	-$3.18 million	$0.06	924.65
ADMA Biologics	$258.21 million	19.38	-$28.24 million	$0.28	76.68

Vericel has higher earnings, but lower revenue than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Vericel has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Insider & Institutional Ownership

75.7% of ADMA Biologics shares are owned by institutional investors. 5.2% of Vericel shares are owned by company insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

ADMA Biologics beats Vericel on 9 of the 15 factors compared between the two stocks.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.